Does the media favor ACAD or OMER?

In the previous week, Omeros had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for Omeros and 8 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.40 beat Omeros' score of 0.41 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, OMER or DYN?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 15.05 Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A

Is OMER or DYN more profitable?

Dyne Therapeutics' return on equity of -64.30% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Dyne Therapeutics N/A -64.30% -50.33%

Does the media refer more to OMER or DYN?

In the previous week, Dyne Therapeutics had 13 more articles in the media than Omeros. MarketBeat recorded 24 mentions for Dyne Therapeutics and 11 mentions for Omeros. Omeros' average media sentiment score of 0.41 beat Dyne Therapeutics' score of 0.28 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, EWTX or OMER?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Omeros N/A N/A -$3.35M $1.28 15.05

Is EWTX or OMER more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Omeros N/A -164.92% 69.41%

Does the media favor EWTX or OMER?

In the previous week, Omeros had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Omeros and 7 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.16 beat Omeros' score of 0.41 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CELC or OMER?

Celcuity is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Omeros N/A N/A -$3.35M $1.28 15.05

Is CELC or OMER more profitable?

Omeros' return on equity of -164.92% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Omeros N/A -164.92% 69.41%

Does the media favor CELC or OMER?

In the previous week, Omeros had 1 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for Omeros and 10 mentions for Celcuity. Omeros' average media sentiment score of 0.41 beat Celcuity's score of 0.30 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Omeros 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, OMER or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 15.05 Parabilis Medicines N/A N/A N/A N/A N/A

Is OMER or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Parabilis Medicines N/A N/A N/A

Does the media favor OMER or PBLS?

In the previous week, Omeros had 7 more articles in the media than Parabilis Medicines. MarketBeat recorded 11 mentions for Omeros and 4 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat Omeros' score of 0.41 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Omeros (OMER) Competitors

$19.27 +0.64 (+3.44%)

As of 08/21/2026 04:00 PM Eastern

Compare

OMER vs. ACAD, DYN, EWTX, CELC, and PBLS

Should you buy Omeros stock or one of its competitors? Omeros's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Edgewise Therapeutics (EWTX), Celcuity (CELC), and Parabilis Medicines (PBLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Omeros compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

ACADIA Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Omeros has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

In the previous week, Omeros had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for Omeros and 8 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.40 beat Omeros' score of 0.41 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Omeros' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Omeros	N/A	-164.92%	69.41%

ACADIA Pharmaceuticals has higher revenue and earnings than Omeros. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.74	$391M	$2.22	13.29
Omeros	N/A	N/A	-$3.35M	$1.28	15.05

ACADIA Pharmaceuticals currently has a consensus price target of $34.19, suggesting a potential upside of 15.91%. Omeros has a consensus price target of $38.00, suggesting a potential upside of 97.20%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Omeros on 10 of the 16 factors compared between the two stocks.

How does Omeros compare to Dyne Therapeutics?

Omeros (NASDAQ:OMER) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Omeros has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

48.8% of Omeros shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Dyne Therapeutics had 13 more articles in the media than Omeros. MarketBeat recorded 24 mentions for Dyne Therapeutics and 11 mentions for Omeros. Omeros' average media sentiment score of 0.41 beat Dyne Therapeutics' score of 0.28 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics' return on equity of -64.30% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Omeros currently has a consensus price target of $38.00, suggesting a potential upside of 97.20%. Dyne Therapeutics has a consensus price target of $34.42, suggesting a potential upside of 31.86%. Given Omeros' higher possible upside, research analysts plainly believe Omeros is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	15.05
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Summary

Omeros beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Omeros compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	15.05

Edgewise Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Omeros has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market.

In the previous week, Omeros had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Omeros and 7 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.16 beat Omeros' score of 0.41 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics currently has a consensus target price of $50.33, suggesting a potential upside of 13.93%. Omeros has a consensus target price of $38.00, suggesting a potential upside of 97.20%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Edgewise Therapeutics' return on equity of -39.01% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Omeros	N/A	-164.92%	69.41%

48.8% of Omeros shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Omeros beats Edgewise Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Omeros compare to Celcuity?

Celcuity (NASDAQ:CELC) and Omeros (NASDAQ:OMER) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Celcuity is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	15.05

In the previous week, Omeros had 1 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for Omeros and 10 mentions for Celcuity. Omeros' average media sentiment score of 0.41 beat Celcuity's score of 0.30 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omeros	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros' return on equity of -164.92% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Omeros	N/A	-164.92%	69.41%

Celcuity has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Omeros has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

Celcuity presently has a consensus target price of $154.55, indicating a potential upside of 65.24%. Omeros has a consensus target price of $38.00, indicating a potential upside of 97.20%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

63.3% of Celcuity shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 13.3% of Celcuity shares are held by company insiders. Comparatively, 10.5% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Omeros beats Celcuity on 10 of the 14 factors compared between the two stocks.

How does Omeros compare to Parabilis Medicines?

Omeros (NASDAQ:OMER) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Omeros currently has a consensus price target of $38.00, indicating a potential upside of 97.20%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 5.86%. Given Omeros' higher probable upside, analysts plainly believe Omeros is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Omeros had 7 more articles in the media than Parabilis Medicines. MarketBeat recorded 11 mentions for Omeros and 4 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat Omeros' score of 0.41 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Parabilis Medicines' return on equity of 0.00% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Parabilis Medicines	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	15.05
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Omeros beats Parabilis Medicines on 5 of the 9 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.39B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	15.05	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	10.30	105.14	78.62	53.99
Price / Book	-27.14	16.80	13.05	6.20
Net Income	-$3.35M	-$12.50M	$3.47B	$348.59M
7 Day Performance	12.10%	3.29%	2.09%	0.08%
1 Month Performance	87.45%	8.23%	6.64%	3.88%
1 Year Performance	337.95%	55.05%	25.02%	16.98%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	3.629 of 5 stars	$19.27 +3.4%	$38.00 +97.2%	+338.0%	$1.39B	N/A	15.05	210	Insider Trade
ACAD ACADIA Pharmaceuticals	4.3251 of 5 stars	$29.01 +2.7%	$34.19 +17.9%	+14.6%	$4.87B	$1.07B	13.07	510	Positive News
DYN Dyne Therapeutics	3.3974 of 5 stars	$26.15 +1.8%	$34.42 +31.6%	+107.5%	$4.80B	N/A	N/A	100	Analyst Revision
EWTX Edgewise Therapeutics	2.8056 of 5 stars	$44.04 -0.3%	$49.08 +11.5%	+197.5%	$4.80B	N/A	N/A	60	Analyst Forecast
CELC Celcuity	3.4037 of 5 stars	$92.44 +0.5%	$154.55 +67.2%	+78.4%	$4.49B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. ACAD, DYN, EWTX, CELC, and PBLS

How does Omeros compare to ACADIA Pharmaceuticals?

Summary

How does Omeros compare to Dyne Therapeutics?

Summary

How does Omeros compare to Edgewise Therapeutics?

Summary

How does Omeros compare to Celcuity?

Summary

How does Omeros compare to Parabilis Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. ACAD, DYN, EWTX, CELC, and PBLS

How does Omeros compare to ACADIA Pharmaceuticals?

Which has more risk and volatility, ACAD or OMER?

Does the media favor ACAD or OMER?

Is ACAD or OMER more profitable?

Which has higher earnings & valuation, ACAD or OMER?

Do analysts recommend ACAD or OMER?

Do institutionals and insiders hold more shares of ACAD or OMER?

Summary

How does Omeros compare to Dyne Therapeutics?

Which has more volatility and risk, OMER or DYN?

Do insiders & institutionals believe in OMER or DYN?

Does the media refer more to OMER or DYN?

Is OMER or DYN more profitable?

Do analysts rate OMER or DYN?

Which has better earnings & valuation, OMER or DYN?

Summary

How does Omeros compare to Edgewise Therapeutics?

Which has stronger valuation & earnings, EWTX or OMER?

Which has more volatility & risk, EWTX or OMER?

Does the media favor EWTX or OMER?

Do analysts rate EWTX or OMER?

Is EWTX or OMER more profitable?

Do insiders and institutionals hold more shares of EWTX or OMER?

Summary

How does Omeros compare to Celcuity?

Which has higher earnings & valuation, CELC or OMER?

Does the media favor CELC or OMER?

Is CELC or OMER more profitable?

Which has more volatility and risk, CELC or OMER?

Do analysts recommend CELC or OMER?

Do insiders & institutionals have more ownership in CELC or OMER?

Summary

How does Omeros compare to Parabilis Medicines?

Do analysts recommend OMER or PBLS?

Does the media favor OMER or PBLS?

Is OMER or PBLS more profitable?

Which has preferable earnings and valuation, OMER or PBLS?

Do insiders and institutionals have more ownership in OMER or PBLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools